Apply to trial NCT07303712

A few quick questions so the study team can decide if you might be a fit.

Recruiting

Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization After Y90

The purpose of this study is to determine if baseline liquid biopsy assays (CTC and cf-DNA) as well as single circulating tumor cell-DNA (sCTC DNA) dynamics in the early post-treatment period can predict subsequent treatment response to Y-90 radioembolization in patients with hepatocellular carcinoma (HCC).

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization After Y90

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening